Abstract S4-1: FinXX Final 5-Year Analysis: Results of the Randomised, Open-Label, Phase III Trial in Medium-to-High Risk Early Breast Cancer
Heikki Joensuu(Orion Corporation (Finland)), Henrik Lindman(Uppsala University), Päivi Auvinen(University of Eastern Finland), Minna Tanner(Tampere University Hospital), Johan Ahlgren(Uppsala University), Peter Bono(Dana-Farber Cancer Institute), Riikka Huovinen(Turku University Hospital), R. Kokko, P-L Kellokumpu-Lehtinen(Uppsala University Hospital), Arja Jukkola‐Vuorinen(University of Oulu)
Cited by 14
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k